<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230806059053N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-09-15</date_registration>
      <primary_sponsor>Kashan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of probiotic supplementation on male infertility</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating effect of probiotics supplement on semen quality and expression of genes associated with oxidative stress in sperm of asthenozoospermia patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-14</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>52</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71890</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Basic scienece, Randomization description: Randomization is done by permutation blocks using random allocation software. 6 blocks of size 4 will be used to distribute samples equally between control and intervention groups. In such manner, the number of each patient is given to the software and the patient group (control or intervention) will be determined.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Idiopathic oligoasthenoteratospermia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The group of patients receiving 100 mg capsule of CoQ10 BD and 500 mg capsule of probiotic FamiLact daily for a period of 70 days (after food consumption). The probiotic part of this supplement consists of strains of Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium breu, Bifidobacterium breu, Bifidobacterium breu, Bifidobacterium strum bifidocum. Also, fructo-oligosaccharide is used as a prebiotic (in fact, the food of insects) in this product. Intervention 2: Control group: The group of patients receiving 100 mg capsule of CoQ10 BD (200 mg).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Elahesadat Seyyedhoseini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kashan, Qotb-e Ravandi Blvd</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8715973474</zip>
        <telephone>+98 31 5558 9444</telephone>
        <email>Elaheir.1987@gmail.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Elahesadat Seyyedhoseini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kashan, Qotb-e Ravandi Blvd</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8715973474</zip>
        <telephone>+98 31 5558 9444</telephone>
        <email>Elaheir.1987@gmail.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Definitive diagnosis of idiopathic oligoasthenospermia</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>People who take drugs affecting spermatogenesis such as tamoxifen, HCG, gonadotropin, androgens and cytotoxic drugs such as immunosuppressants, anticonvulsants, and antibiotic or antifungal drugs.
People who have a diet rich in probiotics.
People who have factors with a clear effect on the condition of asthenozoospermia include: varicocele, epididymovarcitis, prostatitis, history of testicular surgery, testicular trauma, testicular torsion, history of intracytoplasmic sperm injection (ICSI), history of chemotherapy, radiotherapy, abnormality. chromosomal abnormalities, cryptorchidism, hypogonadism, recent history of sexually transmitted diseases, pyospermia, smoking, alcohol, drugs, known hormonal disorders, diabetes, known liver and kidney disease, BMI over 30
Unwillingness to cooperate and participate in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N46.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Male infertility, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The group of patients receiving 100 mg capsule of CoQ10 BD and 500 mg capsule of probiotic FamiLact daily for a period of 70 days (after food consumption). The probiotic part of this supplement consists of strains of Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium breu, Bifidobacterium breu, Bifidobacterium breu, Bifidobacterium strum bifidocum. Also, fructo-oligosaccharide is used as a prebiotic (in fact, the food of insects) in this product.</i_keyword>
      <i_keyword>Control group: The group of patients receiving 100 mg capsule of CoQ10 BD (200 mg)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Gene expression. Timepoint: Before the intervention and after the intervention. Method of measurement: Real-time PCR.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Sperm concentration. Timepoint: Before the intervention and after the intervention. Method of measurement: Semen sample analysis.</sec_outcome>
      <sec_outcome>Semen volume. Timepoint: Before the intervention and after the intervention. Method of measurement: Semen sample analysis.</sec_outcome>
      <sec_outcome>Percentage of abnormal sperm morphology. Timepoint: Before the intervention and after the intervention. Method of measurement: Semen sample analysis.</sec_outcome>
      <sec_outcome>Percentage of sperm motility. Timepoint: Before the intervention and after the intervention. Method of measurement: Semen sample analysis.</sec_outcome>
      <sec_outcome>Percentage of sperm progressive motility. Timepoint: Before the intervention and after the intervention. Method of measurement: Semen sample analysis.</sec_outcome>
      <sec_outcome>Total antioxidant capacity (TAC). Timepoint: Before the intervention and after the intervention. Method of measurement: ELISA.</sec_outcome>
      <sec_outcome>Malondialdehyde (MDA) level. Timepoint: Before the intervention and after the intervention. Method of measurement: ELISA.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Vice Chancellor of Research &amp; Technology</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kashan University of Medical Sciences</source_name>
      <source_name>Vice Chancellor of Research &amp; Technology</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-01</approval_date>
        <contact_name>Ethics Committee of Kashan University of Medical Sciences</contact_name>
        <contact_address>5th of Qotb –e Ravandi Blvd., Kashan Kashan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
